medigraphic.com
ISSN 3061-7774 (Electronic)
ISSN 1870-7203 (Print)
Órgano Oficial del Hospital Ángeles Health System

2026, Number 3

<< Back Next >>

Acta Med 2026; 24 (3)

Osseointegration of grafts and bioactive bone substitutes in the management of bone defects or losses in pediatric patients

Zavala LND, Mora RFG, García BP, Domínguez GRC, Hernández RAK, Braña RK, Muñoz HBM, Romero GED, Peña MMF

Language: Spanish
References: 36
Page: 215-221
PDF size: 993.23 Kb.


ABSTRACT

Introduction: bone defects are defined as the lack of a bone segment; tumor and traumatic etiology represent the main cause in pediatric patients. Allografts continue to be the most used treatment, however there are bioactive molecules that promise lower rates of infection, rejection or pseudoarthrosis. Objective: to evaluate the osseointegration of allografts and bioactive bone substitutes (SOB) in the management of pediatric bone defects. Material and methods: a descriptive, retrospective study was carried out analyzing 59 patients with bone defects treated with the placement of allograft or bioactive glass from January 1, 2013 to January 1, 2024, measuring osseointegration based on the ISOLS (International Symposium on Limb Salvage) scale at 6 months post-surgery. Results: 59 patients were included, 59% male vs 41% female, mean age of 12.92 years. Etiology 68% tumor, 20% pseudoarthrosis, 12% traumatic. Predominantly affecting tibia (36%) and femur (31%), using allografts (76.7%) and SOB (24%), ISOLS excellent (78%) or good (12%), the association between type of graft and the resulting ISOLS did not show a statistically significant difference (p = 0.666). Conclusion: both types of grafts promise favorable results, however the difference in the number of patients treated with allografts vs SOB does not allow us to establish a therapeutic advantage of one over the other.


REFERENCES

  1. Hernández-Flores C, Delgado A, Domínguez-Hernández VM. Evaluación biomecánica de un modelo de defecto óseo en tibia de rata. Rev Mex Ing Biomed. 2011; 32 (1): 12-19.

  2. Nauth A, Schemitsch E, Norris B, Nollin Z, Watson JT. Critical-size bone defects: is there a consensus for diagnosis and treatment? J Orthop Trauma. 2018; 32 Suppl 1: S7-11.

  3. Obremskey W, Molina C, Collinge C et al. Current practice in the management of open fractures among orthopaedic trauma surgeons. Part B: management of segmental long bone defects. A survey of Orthopaedic Trauma Association members. J Orthop Trauma. 2014; 28 (8): e203-207.

  4. Vejarano-Solano JC, Ruiz-Semba CF, Ganoza-Arróspide CJ, Hurtado-Fernández JE. Reconstrucción de defectos óseos segmentarios postraumáticos mediante técnica de inducción de membrana. Rev Med Hered. 2015; 26 (2): 76-86.

  5. Keating JF, Simpson AHRW, Robinson CM. The management of fractures with bone loss. J Bone Joint Surg Br. 2005; 87 (2): 142-150.

  6. Hope PG, Cole WG. Open fractures of the tibia in children. J Bone Joint Surg Br. 1992; 74 (4): 546-553.

  7. Buckley SL, Gotschall C, Robertson W Jr, Sturm P, Tosi L, Thomas M et al. The relationships of skeletal injuries with trauma score, injury severity score, length of hospital stay, hospital charges, and mortality in children admitted to a regional pediatric trauma center. J Pediatr Orthop. 1994; 14 (4): 449-453. doi: 10.1097/01241398-199407000-00005.

  8. Sales de Gauzy J, Fitoussi F, Jouve JL, Karger C, Badina A, Masquelet AC. Traumatic diaphyseal bone defects in children. Orthop Traumatol Surg Res. 2012; 98 (2): 220-226.

  9. Gouron R, Deroussen F, Plancq MC, Collet LM. Bone defect reconstruction in children using the induced membrane technique: a series of 14 cases. Orthop Traumatol Surg Res. 2013; 99 (7): 837-843.

  10. Granel H, Bossard C, Nucke L et al. Optimized bioactive glass: the quest for the bony graft. Adv Healthc Mater. 2019; 8 (11): e1801542.

  11. Cueva del CJF, Valdés-Gutiérrez GA, Elizondo-Vázquez F et al. Tratamiento de pérdidas óseas, pseudoartrosis, artrodesis y tumores óseos benignos con un xenoimplante mexicano (estudio clínico). Cir Cir. 2009; 77 (4): 287-291.

  12. Baldwin P, Li DJ, Auston DA, Mir HS, Yoon RS, Koval KJ. Autograft, allograft, and bone graft substitutes: clinical evidence and indications for use in the setting of orthopaedic trauma surgery. J Orthop Trauma. 2019; 33 (4): 203-213.

  13. García-Gareta E, Coathup MJ, Blunn GW. Osteoinduction of bone grafting materials for bone repair and regeneration. Bone. 2015; 81: 112-121.

  14. Shibuya N, Jupiter DC. Bone graft substitute: allograft and xenograft. Clin Podiatr Med Surg. 2015; 32 (1): 21-34.

  15. Wopenka B, Pasteris JD. A mineralogical perspective on the apatite in bone. Materials Science and Engineering. 2005; C 25 (2): 131-143.

  16. Mouriño V, Cattalini JP, Roether JA, Dubey P, Roy I, Boccaccini AR. Composite polymer-bioceramic scaffolds with drug delivery capability for bone tissue engineering. Expert Opin Drug Deliv. 2013; 10 (10): 1353-1365.

  17. Garg T, Singh O, Arora S, Murthy R. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst. 2012; 29 (1): 1-63.

  18. Albareda J, Sueiro-Fernández J, Zamora RJM. Injertos óseos versus sustitutos óseos. ResearchGate. 2011.

  19. Martínez CA, Ozols A. Biomateriales utilizados en cirugía ortopédica como sustitutos del tejido óseo. Rev Asoc Argent Ortop Traumatol. 2012; 77 (2): 140-46.

  20. Heikkila JT, Kukkonen J, Aho AJ, Moisander S, Kyyrönen T, Mattila K. Bioactive glass granules: a suitable bone substitute material in the operative treatment of depressed lateral tibial plateau fractures: a prospective, randomized 1-year follow-up study. J Mater Sci Mater Med. 2011; 22 (4): 1073-1080.

  21. Lindfors NC, Koski I, Heikkila JT, Mattila K, Aho AJ. A prospective randomized 14-year follow-up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors. J Biomed Mater Res B Appl Biomater. 2010; 94 (1): 157-164.

  22. Kargozar S, Baino F, Hamzehlou S, Hill RG, Mozafari M. Bioactive glasses: sprouting angiogenesis in tissue engineering. Trends Biotechnol. 2018; 36 (4): 430-444.

  23. Kargozar S, Montazerian M, Hamzehlou S, Kim HW, Baino F. Mesoporous bioactive glasses: promising platforms for antibacterial strategies. Acta Biomater. 2018; 81: 1-19.

  24. Rodríguez-Rodríguez EI, Taura-Suárez L. Tumores óseos en edad pediátrica. AMC. 2019; 23 (5): 681-693.

  25. Mora RFG, Bustamante TBB, Mejía RLC, et al. Frecuencia de tumores óseos benignos en niños. Rev Esp Med Quir. 2012; 17 (3): 179-185.

  26. Plaza D, Sastre A, García-Miguel P. Tumores óseos. An Pediatr Contin. 2008; 6 (5): 266-275.

  27. Brito RA, Martínez SI, Torres MA, et al. Fracturas con pérdida ósea segmentaria en niños. Reporte de dos casos tratados con injerto corticoesponjoso autólogo. Acta Ortop Mex. 2006; 20 (6): 289-293.

  28. Gentile L, Iglesias SL, Lobos Centeno E, Vanoli F, Allende Nores CA. Defectos óseos diafisarios postraumáticos en la extremidad superior de niños. Rev Asoc Argent Ortop Traumatol. 2017; 82 (4): 277-293.

  29. López-Martínez JJ, García-Sandoval PP, Fernández-Hernández JA et al. Funcionalidad y osteointegración de los aloinjertos óseos en osteosarcomas de huesos largos. Acta Ortop Mex. 2012; 26 (1): 30-34.

  30. Silva AFS, Criollo PFS. Aloinjerto óseo estructural en cirugía de salvamento de extremidades. Revisión teórica. Quito. 2021; 3 (1): 46-61.

  31. Aponte-Tinao L, Ayerza MA, Muscolo DL, Farfalli GL. Survival, recurrence, and function after epiphyseal preservation and allograft reconstruction in osteosarcoma of the knee. Clin Orthop Relat Res. 2015; 473 (5): 1789-1796.

  32. Jorge FD, Varaona JM, Basso M. Uso de aloinjerto estructural e infecciones posquirúrgicas. Rev Asoc Argent Ortop Traumatol. 2022; 87 (1): 23-33.

  33. Uzcátegui J, Gabaldón L, Rivas A, Brito M, Cosse J. Reconstrucción del húmero con aloinjerto masivo tras resección en bloque por sarcoma de Ewing. Evolución a largo plazo. A propósito de un caso. Revista Venezolana de Cirugía Ortopédica y Traumatología. 2016; 48 (1).

  34. Haugen HJ, Lyngstadaas SP, Rossi F, Perale G. Bone grafts: which is the ideal biomaterial? J Clin Periodontol. 2019; 46 Suppl 21: 92-102. doi: 10.1111/jcpe.13058.

  35. Dinopoulos H, Dimitriou R, Giannoudis PV. Bone graft substitutes: what are the options? Surgeon. 2012; 10 (4): 230-209.

  36. Pelissier P, Masquelet AC, Bareille R, Pelissier SM, Amedee J. Induced membranes secrete growth factors including vascular and osteoinductive factors and could stimulate bone regeneration. J Orthop Res. 2004; 22 (1): 73-79. doi: 10.1016/S0736-0266(03)00165-7.




2020     |     www.medigraphic.com